Kornimate/medical-research-clean huggingface dataset:
radiomics-based prediction model of tumor spread through air space in lung adenocarcinoma

Conditions: Lung Adenocarcinoma

Summary: spread through air space (stas) has been reported as a negative prognostic factor in patients with lung cancer undergone sublobar resection. its preoperative assessment could thus be useful to customize surgical treatment. radiomics has been recently proposed to predict stas in patients with lung adenocarcinoma. however, all the studies have strictly selected both imaging and patients, leading to results hardly applicable to daily clinical practice. the aim of this study is to test a radiomics-based prediction model of stas in practice-based dataset and verify its validity and translational potentials. radiological and clinical data from 100 consecutive patients with resected lung adenocarcinoma were retrospectively collected for the training section. as in common clinical practice, preoperative ct images were acquired independently by different physicians and from different hospitals. therefore, our dataset presents high variance in model and manufacture of scanner, acquisition and reconstruction protocol, endovenous contrast phase and pixel size. to test the effect of normalization in highly varying data, preoperative ct images and tumor region of interest were preprocessed with four different pipelines. features were extracted using pyradiomics and selected considering both separation power and robustness within pipelines. after that, a radiomics-based prediction model of stas were created using the most significant associated features. this model were than validated in a group of 50 patients prospectively enrolled as external validation group to test its efficacy in stas prediction.


Eligibility criteria:
inclusion criteria: * patients with suspected or cito-histologically proven lung adenocarcinoma undergoing lung cancer surgery; * available preoperative ct images * age older than 18 years exclusion criteria: * chest wall infiltration * induction radio or chemotherapy * incomplete surgical resection

Keywords: spread through air space; radiomics
the prevalence and risk factors of irritable bowel syndrome among adults

Conditions: Irritable Bowel Syndrome; Colonic Diseases, Functional

Summary: this is a multicenter cross-sectional study on the prevalence of irritable bowel syndrome and the risk factors associated with it. the rome iv criteria is used for diagnosing ibs. a questionnaire-guided interview will be applied to all subjects.

: irritable bowel syndrome (ibs) is a common functional bowel disorder characterized by abdominal pain or discomfort associated with defecation or an altered bowel habit. ibs can be divided into four subtypes according to the predominant bowel pattern: diarrhea-predominant (ibs-d), constipation-predominant (ibs-c), and both diarrhea and constipation (ibs-m), and when a stool pattern cannot be categorized under any of the above three patterns (ibs-u). for clinicians, diagnosis of ibs can be challenging because symptoms can be variable over time, and what makes it a real challenge is the absence of a gold diagnostic standard for this syndrome. that is why experts developed the rome criteria in 2006, which is constantly revised. the latest update of these criteria was published in 2016 as rome iv. unfortunately, studies have indicated higher rates of psychological comorbidity including suicidal ideation and depression among ibs patients, and a significant reduction in health-related quality of life, this negatively affects the productivity of the individual in society. epidemiological studies of this syndrome have indicated a greater prevalence among women than men, and adolescents among other age groups. however, despite these attempts by researchers to determine the prevalence patterns and risk factors for this syndrome, many of them are still not sufficiently defined. hence, our study came to determine the prevalence and risk factors of irritable bowel syndrome among adults.

Eligibility criteria:
inclusion criteria: * volunteer to participate in the study exclusion criteria: * poorly-controlled hyperthyroidism * poorly-controlled hypothyroidism * poorly-controlled hyperparathyroidism * liver disease * paralysis * parasitic diseases (worms ...) * celiac disease * inflammatory bowel disease (crohn's disease or ulcerative colitis) * lactose intolerance * cancer or tumor in the digestive tract

Keywords: rome iv criteria colonic diseases digestive system diseases irritable bowel syndrome
a comparison of two daily disposable contact lenses.

Conditions: Refractive Error; Myopia

Summary: this study seeks to evaluate the clinical fitting performance of a new daily disposable contact lens to an existing daily disposable contact lens.


Eligibility criteria:
inclusion criteria: * they are of legal age (18 years) and capacity to volunteer. * they understand their rights as a research subject and are willing to sign a statement of informed consent. * they are willing and able to follow the protocol. * they would be expected to attain at least 6/9 (20/30) in each eye with the study lenses. * they are able to wear contact lenses with a back vertex power of -1.00 to -6.00ds. * they have a maximum of 1.00d of refractive astigmatism (i.e. ≤ 1.00 dc). * they have successfully worn contact lenses within six months of starting the study. exclusion criteria: * they have an ocular disorder which would normally contra-indicate contact lens wear. * they have a systemic disorder which would normally contra-indicate contact lens wear. * they are using any topical medication such as eye drops or ointment. * they are aphakic. * they have had corneal refractive surgery. * they have any corneal distortion resulting from previous hard or rigid lens wear or has keratoconus. * they are pregnant or lactating. * they have grade 2 or greater of any of the following ocular surface signs: corneal oedema, corneal vascularisation, corneal staining, tarsal conjunctival changes or any other abnormality which would normally contraindicate contact lens wear. * they have any infectious disease (e.g. hepatitis) or any immunosuppressive disease (e.g. hiv). * they have diabetes. * they have taken part in any other clinical trial or research, within two weeks prior to starting this study.
open-label study of perhexiline in patients with hypertrophic cardiomyopathy and moderate to severe heart failure

Conditions: Cardiomyopathy, Hypertrophic; Cardiomyopathy, Hypertrophic, Familial

Summary: the purpose of this study is to evaluate the effect of perhexiline on exercise performance (efficacy) and safety in patients with hypertrophic cardiomyopathy and moderate-to-severe heart failure following dosing for 16 weeks.

patients with hypertrophic cardiomyopathy and symptoms without severe outflow obstruction will be eligible to participate. enrollment will be limited to subjects who are unable to attain 75% of their maximum predicted mvo2 at cardiopulmonary exercise testing. subjects with genetic evidence of cyp2d6 poor metabolizer status will be excluded. subjects will undergo functional testing at baseline with cpex testing and 6 minute walk distance testing. they will begin perhexiline orally, and the dose will be adjusted according to plasma level testing. for the first 8 week period, the target therapeutic range will be 100-300 ng/ml, and for the second 8 week period, the range will be 300-500 ng/ml. functional testing will be repeated at the end of both periods.

Eligibility criteria:
key inclusion criteria: * hypertrophic cardiomyopathy with symptoms of moderate-to-severe heart failure * left ventricular hypertrophy with maximum lv wall thickness ≥ 15 mm * left ventricular ejection fraction ≥ 50% * able to perform exercise testing but unable to exceed 75% of the predicted age-adjusted maximum level key exclusion criteria: * cyp2d6 poor metabolizer (pm) status * history of a known chronic liver disease * alt, ast, alkaline phosphatase, or ldh \> 1.5 x upper limit of normal * total bilirubin \> 2.0 x upper limit of normal * severe lv outflow obstruction * asymptomatic patients or cardiomyopathy-related criteria as per protocol * qt interval related criteria as per protocol

Keywords: hypertrophic cardiomyopathy heart failure cardiopulmonary exercise testing 6 minute walk test perhexiline carnitine palmitoyltransferase mixed ion channel effects late sodium current inhibitor calcium channel inhibition
total neoadjuvant treatment combined with adaptive radiotherapy for rectal cancer

Conditions: Rectal Cancer

Summary: diarrhea was the most frequently reported severe adverse event in the treatment regime of pre-operative sequential short-course radiotherapy followed by chemotherapy (so called total neo-adjuvant treatment). this study therefore investigates the benefit of on-couch adaptation for locally advanced rectal cancer patients undergoing this treatment regime.

this is a prospective single-arm study investigating the benefit of on-couch adaptation for locally advanced rectal cancer patients prescribed with pre-operative sequential short-course radiotherapy (rt) followed by oxaliplatin-combined chemotherapy (mfolfox(6) or capox). on-couch adaptation, where the radiation dose is tailored to the anatomy of the patient at each radiotherapy session. firstly, the study will investigate if on-couch adaptation result in less gastro-intestinal adverse events, secondly it will reveal if this possible reduction lead to more patients being able to fulfill all cycles of prescribed chemotherapy.

Eligibility criteria:
inclusion criteria: * patients with loco-regional advanced rectal adenocarcinoma with clinical indications for short-course with tnt chemotherapy i.e. having at least one of the following t4a, crm+ (≤1 mm), n1c, n2 or extramural vascular invasion (emvi+). patients presenting at least one of these criteria in addition to involvement of the pelvic sidewall lymph nodes (psw) can optionally be considered. * ecog status ≤ 1 * being willing and able to give full written consent for participation exclusion criteria: * previous rectal cancer treatment * previous irradiation to the treatment area e.g. prostate cancer * hip prosthesis * contraindications to mri * pregnancy * abnormal dpyd genotype * known contraindication to 5-fu, capecitabine or oxaliplatin as judged by the investigators
effect of heat stress on global lv function in anesthetized humans

Conditions: Hyperthermia; Cardiac Functional Disturbances During Surgery

Summary: recent data suggests that increased temperature improves inotropic function during systole and may improve diastolic function in healthy humans at rest, despite a reduction in left ventricular volume at end diastole. the effect of heat stress has not been reported in patients receiving general anesthesia and the impact of general anesthesia on these findings is not known. trans-esophageal echocardiography will be used to measure parameters important to both systolic and diastolic function at temperature intervals of 1°c in patients undergoing "heated intraoperative peritoneal chemotherapy" (hipec.) that general anesthesia will not alter the cardiovascular effects of increased temperature that has been reported in healthy, un-anesthetized humans is the hypothesis.


Eligibility criteria:
inclusion criteria: * any patient presenting for hyperthermic intraperitoneal chemotherapy. exclusion criteria: * subjects less than 18 years old. * pregnant women * prisoners, * institutionalized individuals * any patient with known contraindication to transesophageal echocardiography. * patients with known cardiac dysfunction prior to screening will be excluded.
phase ii randomized study of physiologic testosterone replacement in premenopausal, hiv-positive women

Conditions: HIV Infections; Cachexia

Summary: objectives: i. determine whether physiologic testosterone replacement can increase fat-free mass, therefore contributing to weight maintenance, improved muscle function, and quality of life in hiv-infected women. ii. examine the mechanism of testosterone-induced increase in fat-free mass.

protocol outline: this is a randomized, double blind, placebo controlled study. patients are randomized to one of three arms. arm i: patients receive two placebo transdermal patches applied twice a week (every 3-4 days). arm ii: patients receive one testosterone transdermal patch and one placebo transdermal patch applied twice a week (every 3-4 days). arm iii: patients receive two testosterone transdermal patches applied twice a week (every 3-4 days). patients receive 12 weeks of treatment in the absence of adverse reaction or health deterioration. patients are followed on day 1, every 2 weeks during treatment, and at the end of the recovery period. quality of life is assessed before treatment begins and at weeks 6 and 12. completion date provided represents the completion date of the grant per oopd records

Eligibility criteria:
protocol entry criteria: --disease characteristics-- * histologically confirmed premenopausal hiv-positive women who have experienced 5-15% weight loss --prior/concurrent therapy-- * endocrine therapy: at least 3 months since megestrol at least 3 months since anabolic or androgenic steroids at least 3 months since oral contraceptives at least 3 months since depo-provera no concurrent hormone replacement therapy * other: concurrent retroviral or protease inhibitors allowed, dosage must be stable at least 3 months since ketoconazole at least 6 weeks since the initiation of protease inhibitors --patient characteristics-- * hepatic: no significant liver disease sgot/sgpt no greater than 3 times upper limit of normal (uln) alkaline phosphatase no greater than 3 times uln bilirubin no greater than 2 mg/dl no medical complications due to alcohol abuse * renal: not specified * cardiovascular: no significant cardiovascular disease no uncontrolled hypertension * other: testosterone level (early morning) less than 30 ng/dl normal gastrointestinal function as indicated by: absence of diarrhea normal d-xylose absorption test no acute opportunistic infections or infectious illness no malignant disease no history of breast cancer no history of endometrial cancer no fever of known or unknown origin no unremitting diarrhea defined as: at least 4 watery stools per day or more than 4 watery stools recently or acute change in stool habit with fever no significant respiratory disease no diabetes no illicit drugs within the past 6 months no history of hyperandrogenic disorders such as: hirsutism polycystic ovary disease not pregnant or lactating

Keywords: cachexia disease-related problem/condition human immunodeficiency virus infection immunologic disorders and infectious disorders nutrition quality of life rare disease viral infection
intravenous iron in gynecologic cancer patients receiving chemotherapy

Conditions: Gynecologic Cancer

Summary: can intravenous iron lower the rate of blood transfusion in gynecologic cancer patients receiving platinum based chemotherapy than oral iron?

anemia is a common condition during chemotherapy administration. treatment options usually include oral iron supplementation and blood transfusion. however, oral iron has gastrointestinal side effects, which affects patient compliance, and only a small amount of oral iron can be absorbed from the gastrointestinal tract. intravenous iron may overcome a block of iron absorption and iron recycling induced by hepcidin. therefore, it may increase hemoglobin level and reduced blood transfusion in cancer patients receiving chemotherapy.

Eligibility criteria:
inclusion criteria: * age 20-70 years * good performance status (zubrod score \< 2) * no serious underlying disease * normal renal function test * normal liver function test * platinum based chemotherapy is the first line regimen * no prior or receiving radiotherapy exclusion criteria: * iron hypersensitivity * underlying disease which has the risk of iron overload such as chronic kidney disease, major thalassemia * progressive disease * bone marrow metastasis

Keywords: intravenous iron gynecologic cancer blood transfusion
clinical management and outcomes of primary ovarian leiomyosarcoma

Conditions: Primary Ovarian Leiomyosarcoma

Summary: this observational study aims to gather comprehensive data on primary ovarian leiomyosarcoma (polms). this extremely rare malignancy accounts for less than 3% of primary ovarian malignancies and has an incidence of only 1% among ovarian cancers. this national, retrospective and prospective multicenter study will collect and analyze historical cases of polms with remote diagnoses accessed through clinical case reviews and newly identified cases. the study aims to expand a previously identified series of 113 cases described in the literature, uncovering patterns in diagnosis, treatment, and outcomes and ultimately establishing evidence-based guidelines for the optimal management of this rare and aggressive cancer.

this study adopts a national, multicenter, observational design, incorporating both retrospective and prospective methodologies to collect and analyze primary ovarian leiomyosarcoma (polms) cases. the retrospective component will include cases diagnosed since 1980, leveraging institutional archives and clinical case reviews. data collection will be standardized using an electronic case report form (ecrf) implemented on redcap. all data will be centralized for uniformity and undergo rigorous validation to ensure consistency across centers. findings will be reported in aggregated form to preserve patient confidentiality. the study will gather extensive data points, including: * patient demographics. * clinical presentation and tumor characteristics (symptoms, tumor markers such as ca-125, cea, and ki-67). * treatment modalities (surgical details, lymphadenectomy, chemotherapy, radiotherapy, or hormonal therapy). * recurrence patterns and outcomes (disease-free survival, overall survival). * immunohistochemical findings (positivity for desmin, sma, and vimentin). the statistical analysis primarily involves descriptive and exploratory techniques to identify patterns and correlations within the dataset.

Eligibility criteria:
inclusion criteria: * diagnosis of primary leiomyosarcoma of the ovary; * patients diagnosed with polms for whom data relating to diagnosis and treatment are available. * aged between 18 and 99 years exclusion criteria: - all patients with other forms of ovarian sarcoma (rhabdomyosarcomas, fibrosarcomas, stromal cell sarcomas) and patients diagnosed with leiomyosarcoma of the uterus will be excluded.

Keywords: primary ovarian leiomyosarcoma gynecologic oncology neoplasms, muscle tissue neoplasms, connective and soft tissue neoplasms by histologic type sarcoma neoplasms histopathology prognostic factors tumor markers
virtual mirror therapy for relief of chronic phantom limb pain

Conditions: Phantom Limb Pain

Summary: the purpose of this project is to further investigate the use of virtual mirror therapy for alleviating symptoms of chronic phantom limb pain. this initial pilot study will inform a fully powered randomized control trial which will include both upper and lower extremity amputees

ten unilateral upper extremity amputees suffering from chronic phantom limb pain \> 1 yr will be recruited from a hospital based outpatient physical medicine and rehabilitation amputee clinic. there will be no control group and all 10 subjects will be offered the use of a virtual reality headset therapy game (developed in unreal engine using oculus quest 2 sdk). fiducial markers will be placed on the residual limb for tracking via front facing cameras on the oculus quest 2 and the sound limb movements will be duplicated (flipped for chirality) and mapped onto the residual limb to provide the appearance of their residual limb. the software will direct the subjects through a series of guided movements, stretches, and visualization exercises which last a total of 15 minutes. afterwards the subjects will be given 5 minutes of unstructured time in the program to perform any of exercises or movements they desire in order to attempt to relieve their phantom limb pain. subjects will aim for 1 session per week for a total of 6 weeks. subjects will rate their phantom limb pain symptoms on the numeric rating scale (nrs) prior to and after each session. prior to the first session as well as at 6 weeks and 12 weeks subjects will rate their phantom limb pain symptoms on the pain disability

Eligibility criteria:
inclusion criteria: * presence of unilateral upper extremity amputation with continued intermittent or persistent phantom limb pain symptoms \> 1 yr after amputation, pain must be \>=4 of 10 on the vas at least intermittently (i.e. can have no pain at times but they must at least have 4/10 intensity of pain when pain does occur). exclusion criteria: * uncontrolled bipolar/schizophrenia, active psychosis, uncontrolled seizure disorder, history of severe simulator sickness, active nausea/vomiting, uncontrolled vertigo, bilateral blindness, any facial wounds around the cheeks nose or eyes that may interfere with headset, conjunctivitis, zoster ophthalmicus, immunodeficiency (uncontrolled hiv, immuno-suppressive medications, chemotherapy, etc), severe claustrophobia.

Keywords: virtual mirror therapy chronic phantom limb pain
assessing shoulder pathways involving the cuff

Conditions: Rotator Cuff Shoulder Syndrome and Allied Disorders; Rotator Cuff Related Shoulder Pain

Summary: new recommendations regarding care pathways for the management of shoulder pain syndromes have recently been published. we aim to analyze and compare the existing care pathways and identify the most appropriate approaches for different patient profiles. our primary objective is to compare pain levels and shoulder function one year after your initial consultation with your general practitioner for this episode. we also seek to assess which healthcare professionals you consult for your shoulder management, the treatments you receive (e.g., analgesics), and any imaging studies you undergo (if prescribed). we will send you notifications to remind you of the survey completion schedule and provide the link to access the questionnaire. participation in this study requires your commitment and adherence to the timeline, as missing data may compromise the analysis of results. non-participation in the study will not affect your current medical care.


Eligibility criteria:
inclusion criteria: * rotator cuff related shoulder pain * consultation with a general practitionner for this disorder in the 6 weeks prior to the inclusion exclusion criteria: * history of upper limb trauma associated with the current episode of shoulder pain * neurologic or rheumatismal shoulder disorder * frozen shoulder (current or past) * history of advanced glenohumeral athritis * history of shoulder surgery (on the affected side)

Keywords: rotator cuff health economics cost utility incapacity shoulder non-traumatic
investigation on the dynamic changes in air microbiome in intensive care unit

Conditions: Hospital Acquired Infection

Summary: the microbiome of icu, especially the air microbiome of icu is not clear. the relationship between the microbiome of icu and the hospital- acquired infection needs to be clarified. in this study, we try to outline the dynamic changes of microbiome in icu and give some advice on the prevention of hai.


Eligibility criteria:
inclusion criteria: no patients were enrolled in this study. exclusion criteria: no patients were enrolled in this study.

Keywords: microbial colonization environmental exposure microbiome